Drug Trial Radar · NCT02406014
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Apr 2015
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 4, multi-centre, randomized, two group, open label, active controlled, parallel group, 17 week trial.
Conditions
- Actinic Keratosis (AK)
Interventions
Ingenol Mebutate Gel, 0.015%Drug
Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
Diclofenac sodium gel 3%Drug
Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete clearance of all AKsTime frame: 11 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gemain, Weber & Craninic
Schweinfurt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.